CD19 and non-Hodgkin lymphoma: Notably, the first approved T cell engager worldwide, BLINCYTO® (blinatumomab) (CD19-targeting), although approved as a CIV formulation, has since been tested as a SC formulation in both Relapsed/Refractory indolent Non-Hodgkin’s Lymphoma (NHL) and Acute Lymphoblastic Leukemia (ALL).